These results indicate that repeated injection of Tg2-rich wildtype MV- during the growth of MDA- (shTg2) primary tumors resulted in primary tumor stiffening, increased fibroblast activation, and increased metastasis of the Tg2-knockdown weakly migratory breast cancer subpopulation. Here, TGM2 is linked to breast cancer.